VAC17 Antibody

What is VAC17 and why is it important for cellular research?

VAC17 is a myosin-dependent adaptor protein essential for vacuole transport in yeast (Saccharomyces cerevisiae). It serves as a bridge between vacuole vesicles and actin cables by interacting with Vac8 (on vacuole vesicles) and the Myo2 motor protein (on actin cables) . VAC17 plays crucial roles in asymmetric inheritance of aggregated proteins, endocytosis, and vesicle trafficking. Recent research demonstrates that VAC17 is required for mother cell-biased segregation of protein aggregates and can extend replicative lifespan when overproduced . This positions VAC17 as a significant target for studies on aging and cellular quality control mechanisms.

Why is VAC17 detection challenging in standard laboratory protocols?

Detecting VAC17 presents significant challenges due to its extremely low abundance—approximately 20 copies per cell . This low expression level makes VAC17 difficult to detect using standard immunoblotting techniques. Additionally, VAC17 undergoes rapid turnover mediated by the ubiquitin-proteasome system, further reducing steady-state protein levels available for detection . Researchers have overcome these limitations by using epitope-tagged versions (VAC17-GFP or VAC17-TAP) expressed from plasmids, which provide sufficient signal for detection while maintaining functionality . For studying specific phosphorylated forms, specialized phospho-specific antibodies (such as anti-phosphoThr240) combined with immunoprecipitation have proven effective .

What controls should be included when using VAC17 antibodies?

When designing experiments with VAC17 antibodies, several essential controls should be incorporated:

• Negative controls: Include samples from vac17Δ deletion strains to confirm antibody specificity and identify non-specific bands .

• Phosphorylation-specific controls: For phospho-specific VAC17 antibodies, include lambda phosphatase-treated samples alongside phosphatase inhibitor-treated and untreated samples to demonstrate phospho-specificity .

• Positive controls: Use samples from strains overexpressing VAC17 or from dma1Δ dma2Δ mutants where phosphorylated VAC17 accumulates due to reduced degradation .

• Interaction controls: In co-immunoprecipitation experiments, include controls with known VAC17 interaction partners (such as the Myo2 cargo binding domain) to validate experimental conditions .

How can I effectively visualize VAC17 localization in living cells?

Due to the low abundance and dynamic behavior of VAC17, specialized approaches are required for effective visualization:

• Fluorescent protein tagging: C-terminal GFP tagging of VAC17 expressed from plasmids provides sufficient signal for fluorescence microscopy while maintaining functionality .

• Imaging platform: Time-lapse imaging using a DeltaVision Restoration system with an inverted epifluorescence microscope (such as IX-71; Olympus) and a charge-coupled device camera (Cool-SNAP HQ; Photometrics) has been successfully used to capture VAC17 dynamics .

• Vacuole co-visualization: Combining VAC17-GFP with vacuole membrane staining using FM4-64 (12 μg in 250 μL media for 1 hour, followed by washing and 2-3 hours of growth) allows simultaneous visualization of VAC17 and vacuoles .

• Protein aggregate co-localization: For studying VAC17's association with protein aggregates, dual-color imaging with VAC17-GFP and Hsp104-mCherry (a marker for protein aggregates) enables assessment of spatial relationships during cellular stress responses .

What are the optimal approaches for studying VAC17 phosphorylation states?

Studying VAC17 phosphorylation requires specialized techniques due to the transient nature of these modifications:

• Phospho-specific antibodies: Antibodies targeting specific phosphorylation sites (such as phospho-Thr240) can detect these modifications in immunoblotting experiments .

• Genetic stabilization: Utilizing dma1Δ dma2Δ mutant backgrounds where degradation of phosphorylated VAC17 is impaired significantly enhances detection of phosphorylated forms .

• Phosphorylation validation: Lambda phosphatase treatment of immunoprecipitated VAC17 samples can confirm phospho-specificity by demonstrating mobility shifts in gel electrophoresis and loss of antibody recognition .

• Site-directed mutagenesis: Point mutations at phosphorylation sites (such as T240A) can be used to confirm the specificity of phospho-antibodies and investigate the functional significance of specific phosphorylation events .

How can I optimize VAC17 ubiquitylation studies?

Studying VAC17 ubiquitylation requires careful experimental design:

Research has demonstrated that VAC17 is ubiquitylated in vivo in a Dma1/Dma2-dependent manner, with this modification targeting VAC17 for degradation via the proteasome .

How does VAC17 contribute to asymmetric inheritance of protein aggregates?

VAC17 plays a critical role in the asymmetric inheritance of heat-induced protein aggregates, contributing to cellular rejuvenation mechanisms:

• Retention function: VAC17 predominantly affects the retention of protein aggregates in mother cells rather than their removal, ensuring daughters receive fewer damaged proteins .

• Vacuole-aggregate association: Approximately one-third of cells show co-localization between VAC17 and Hsp104 aggregates, suggesting VAC17 associates with misfolded/aggregated proteins .

• Substrate specificity: VAC17 specifically regulates heat-induced misfolded proteins but does not affect the retention of amyloidic proteins like Huntingtin Htt103QP, indicating pathway-specific functions .

• Myo2-dependent mechanism: Similar to its role in vacuole inheritance, VAC17's function in aggregate retention requires interaction with the Myo2 motor protein and the actin cytoskeleton .

Research demonstrates that deletion of VAC17 significantly impairs mother cell-biased segregation of aggregates, highlighting its importance in cellular quality control mechanisms .

What techniques can quantify VAC17-dependent aggregate retention?

Quantifying VAC17's role in aggregate retention requires specialized approaches:

• Aggregate induction: Heat shock protocols (42°C for 30 minutes) followed by recovery at normal temperature (30°C) can be used to induce protein aggregation in a controlled manner .

• Visualization: Fluorescent tagging of aggregate markers like Hsp104-GFP enables visualization of aggregates in living cells .

• Scoring methodology: Manual quantification of aggregate distribution between mother and daughter cells in large-budded cells (typically examining 100-200 cells per experiment in triplicate) provides robust data .

• Discrimination protocols: Specialized protocols that distinguish between effects on aggregate retention versus aggregate removal help pinpoint VAC17's specific contributions .

• Retention factor calculation: Calculate an aggregate retention factor by determining the percentage of budded cells where aggregates are retained exclusively in the mother cell versus those showing inheritance in daughter cells .

How does VAC17 overexpression affect cellular aging and protein quality control?

Overexpression of VAC17 has significant impacts on cellular aging and protein quality control mechanisms:

• Lifespan extension: VAC17 overproduction extends replicative lifespan in yeast, suggesting it enhances cellular quality control mechanisms .

• Enhanced aggregate sequestration: Increased VAC17 levels promote deposition of protein aggregates into cytoprotective vacuole-associated sites, improving aggregate management .

• Preservation of cellular functions: VAC17 overexpression counteracts age-related breakdown of endocytosis and vacuole integrity, two key physiological aspects of cellular aging .

• Mechanistic connection: The connection between damage asymmetry and vesicle trafficking can be explained by direct interactions between aggregates and vesicles, with VAC17 serving as a critical mediator .

These findings highlight VAC17 as a potential target for interventions aimed at improving cellular proteostasis and extending healthy lifespan.

Why might VAC17 antibodies fail to detect the protein despite proper technique?

Several factors may contribute to detection failures with VAC17 antibodies:

• Extremely low abundance: With only approximately 20 copies per cell, VAC17 may be below detection thresholds for standard immunoblotting techniques .

• Rapid protein turnover: VAC17 undergoes rapid ubiquitin-mediated degradation, reducing steady-state levels available for detection .

• Post-translational modifications: Phosphorylation or ubiquitylation may mask antibody epitopes or alter protein mobility on gels .

• Technical limitations: Standard transfer conditions may not be optimal for proteins of VAC17's molecular characteristics.

Solutions include increasing starting material (5-10× more cells than standard protocols), using epitope-tagging strategies (VAC17-GFP, VAC17-TAP), employing genetic backgrounds that stabilize VAC17 (dma1Δdma2Δ or proteasome mutants), and including proteasome inhibitors in lysis buffers .

How can non-specific bands be distinguished from authentic VAC17 signals?

Distinguishing specific from non-specific signals requires methodical approaches:

• Genetic controls: Always include vac17Δ strains as negative controls to identify truly VAC17-specific bands .

• Epitope tagging: Use tagged versions of VAC17 that can be detected with highly specific commercial tag antibodies .

• Enrichment techniques: Perform immunoprecipitation before immunoblotting to concentrate VAC17 and reduce background .

• Molecular weight verification: VAC17 runs at approximately 62 kDa, with phosphorylated and ubiquitylated forms appearing as higher molecular weight species .

• Antibody validation: For phospho-specific antibodies, confirm specificity through lambda phosphatase treatment to demonstrate phospho-dependent recognition .

What factors might affect VAC17-protein interaction studies?

When investigating VAC17's interactions with other proteins, several factors can impact results:

• Transient interactions: VAC17 forms dynamic complexes with partners like Dma1, which may be difficult to capture without stabilization strategies .

• Competition for binding: VAC17 competes with other adaptor proteins for recruitment to the Myo2 motor protein, potentially affecting interaction strength under different conditions .

• Conformational changes: Phosphorylation of VAC17 at Thr240 significantly affects its interaction with binding partners like Dma1 .

• Degradation during preparation: Rapid ubiquitin-mediated turnover of VAC17 may result in loss of interactions during sample preparation .

Using crosslinking approaches, ubiquitylation-defective mutants (e.g., dma1-I329R), and in vitro binding assays with recombinant proteins can help overcome these challenges .

How might VAC17 antibodies facilitate investigations into neurodegenerative diseases?

While VAC17 has been primarily studied in yeast, its role in protein aggregate management suggests potential relevance to neurodegenerative conditions:

• Ortholog identification: VAC17 antibodies could help identify potential mammalian orthologs based on structural or functional similarity.

• Comparative studies: Investigate whether mammalian proteins perform analogous functions in asymmetric inheritance of protein aggregates in dividing neural stem cells.

• Disease-specific applications: Examine whether VAC17-like mechanisms are compromised in models of Huntington's, Parkinson's, or Alzheimer's disease, where protein aggregation is a hallmark.

• Therapeutic targeting: If functional conservation exists, VAC17-related pathways could represent novel therapeutic targets for preventing aggregate accumulation in neurodegenerative disorders.

What technological advances might enhance VAC17 antibody applications?

Emerging technologies could significantly advance VAC17 research:

• Super-resolution microscopy: Techniques like STORM or PALM could enable nanoscale visualization of VAC17's associations with vesicles and protein aggregates.

• Proximity labeling: BioID or APEX approaches with VAC17 as bait could comprehensively identify its interactome under different conditions.

• Mass spectrometry advances: Improved sensitivity in proteomic approaches could enable comprehensive mapping of VAC17 post-translational modifications.

• CRISPR-based approaches: Gene editing technologies could facilitate creation of endogenously tagged VAC17 variants that maintain native expression levels while enabling detection.

• Single-molecule techniques: Methods like single-molecule pull-down could characterize VAC17 interactions at the individual molecule level, revealing heterogeneity in complex formation.

How can VAC17 research contribute to understanding fundamental mechanisms of cellular aging?

VAC17's role at the intersection of vesicle trafficking and protein quality control positions it as an important factor in aging research:

• Asymmetric damage segregation: Further investigation of VAC17-dependent mechanisms could reveal how cells partition damaged components during division to promote rejuvenation .

• Proteostasis decline: Studying how VAC17 function changes during replicative aging could illuminate key aspects of age-related proteostasis collapse.

• Organelle quality control: VAC17's involvement in vacuole inheritance suggests potential roles in maintaining organelle quality throughout cellular aging .

• Stress response integration: Exploring how VAC17 responds to various cellular stresses could reveal how cells coordinate quality control mechanisms under challenging conditions.

Research in these areas could identify intervention points to extend healthy lifespan through enhanced protein quality control and damage segregation mechanisms.